With the evolution of in silico drug development, the reliance on animal testing for predicting human pharmacokinetics (PK) is undergoing a profound paradigm shift, one led by Certara through our Simcyp® and Applied Biosimulation technologies.
However, traditional allometric techniques still play a valuable role, offering efficient and precise estimates of human pharmacokinetics and dose prediction.
Unlike simple allometric scaling of clearance and volume, time-invariant pharmacokinetic (PK) scaling methods such as the Dedrick and Wajima approaches, describe the entire PK time-course, offering greater precision and confidence in predicting human pharmacokinetics than traditional parameter scaling.
Discover how these techniques, seamlessly integrated within the Phoenix® platform’s intuitive workflows, enhance translation from preclinical to clinical studies, streamline dose prediction, and improve first-in-human projections. With Phoenix’s trusted, regulatory-compliant environment and Certara’s deep translational and model-informed expertise, you’ll discover a proven path to faster, smarter, and more confident drug development decisions. Don’t miss this opportunity to refine your modeling toolkit and elevate your quantitative pharmacology strategy.
Key learning objectives:
- Understand the evolving landscape of in silico drug development
- Differentiate between traditional and advanced PK scaling techniques
- Explore time-invariant PK scaling in practice
- Learn to apply advanced PK scaling within Certara Phoenix
- Enhance decision-making in early drug development
This webinar is ideal for:
Pharmacokineticists and Pharmacometricians, Preclinical and Clinical Pharmacologists, Drug Development Scientists / DMPK (Drug Metabolism and Pharmacokinetics) Teams, Regulatory Scientists and Project Leads
Speakers:
- Elliot Offman, BSc Pharm, MSc, PhD
- Rachael Kendrick, PharmD
- Christopher Mehl
